Literature DB >> 35747420

Cancer immunotherapy and its potential cardiac complications.

Simon G Findlay1, Ruth Plummer2, Chris Plummer3.   

Abstract

Recent advances in immune therapy for cancer have significantly improved the clinical outcomes of patients with advanced cancers, where prognosis has historically been very poor. With these new treatments have come new toxicities and, as the use of immunotherapy increases, we will see an increasing incidence of immune-related adverse events, with patients presenting as an emergency. It is important that all cardiologists, and other physicians who see these patients, are aware of life-threatening immune-related toxicities, in addition to their recommended investigation and treatment. We describe a patient with acute cardiotoxicity secondary to immune therapy to illustrate the complexity of these adverse cardiovascular events, providing recommendations for screening, diagnosis and management.
Copyright © 2020 Medinews (Cardiology) Limited.

Entities:  

Keywords:  Immunotherapy; cardio-oncology; cardiotoxicity; immune checkpoint inhibitors

Year:  2020        PMID: 35747420      PMCID: PMC8793930          DOI: 10.5837/bjc.2020.002

Source DB:  PubMed          Journal:  Br J Cardiol        ISSN: 0969-6113


  22 in total

Review 1.  Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders.

Authors:  Athar Haroon; Alimuddin Zumla; Jamshed Bomanji
Journal:  Clin Infect Dis       Date:  2012-03-19       Impact factor: 9.079

Review 2.  Cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Jiun-Ruey Hu; Roberta Florido; Evan J Lipson; Jarushka Naidoo; Reza Ardehali; Carlo G Tocchetti; Alexander R Lyon; Robert F Padera; Douglas B Johnson; Javid Moslehi
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

3.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Authors:  Mario Sznol; Pier Francesco Ferrucci; David Hogg; Michael B Atkins; Pascal Wolter; Massimo Guidoboni; Celeste Lebbé; John M Kirkwood; Jacob Schachter; Gregory A Daniels; Jessica Hassel; Jonathan Cebon; Winald Gerritsen; Victoria Atkinson; Luc Thomas; John McCaffrey; Derek Power; Dana Walker; Rafia Bhore; Joel Jiang; F Stephen Hodi; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2017-09-15       Impact factor: 44.544

4.  Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.

Authors:  Marion Escudier; Jennifer Cautela; Nausicaa Malissen; Yann Ancedy; Morgane Orabona; Johan Pinto; Sandrine Monestier; Jean-Jacques Grob; Ugo Scemama; Alexis Jacquier; Nathalie Lalevee; Jeremie Barraud; Michael Peyrol; Marc Laine; Laurent Bonello; Franck Paganelli; Ariel Cohen; Fabrice Barlesi; Stephane Ederhy; Franck Thuny
Journal:  Circulation       Date:  2017-11-21       Impact factor: 29.690

5.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

6.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Syed S Mahmood; Michael G Fradley; Justine V Cohen; Anju Nohria; Kerry L Reynolds; Lucie M Heinzerling; Ryan J Sullivan; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Magid Awadalla; Malek Z O Hassan; Javid J Moslehi; Sachin P Shah; Sarju Ganatra; Paaladinesh Thavendiranathan; Donald P Lawrence; John D Groarke; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-03-19       Impact factor: 24.094

Review 7.  Cardiovascular Toxicities Associated with Cancer Immunotherapies.

Authors:  Daniel Y Wang; Gosife Donald Okoye; Thomas G Neilan; Douglas B Johnson; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

8.  Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis.

Authors:  Tsuneo Ogawa; John P Veinot; Mercedes L Kuroski de Bold; Tina Georgalis; Adolfo J de Bold
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-04-11       Impact factor: 4.733

9.  Managing cardiotoxicity associated with immune checkpoint inhibitors.

Authors:  Sireesha Upadhrasta; Hadi Elias; Keval Patel; Lei Zheng
Journal:  Chronic Dis Transl Med       Date:  2019-03-21

10.  Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.

Authors:  Mahdieh Fazel; Patrick M Jedlowski
Journal:  Case Reports Immunol       Date:  2019-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.